Jazz Pharmaceuticals To Acquire GW Pharmaceuticals, Creating An Innovative, High-Growth, Global Biopharma Leader

UNITED KINGDOM: Jazz Pharmaceuticals plc and GW Pharmaceuticals announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.

Upon close of the transaction, the combined company will be a leader in neuroscience with a global commercial and operational footprint well positioned to maximize the value of its diversified portfolio.

GW is a global leader in discovering, developing, manufacturing and commercializing novel, regulatory approved therapeutics from its proprietary cannabinoid product platform to address a broad range of diseases. The company’s lead product, Epidiolex® (cannabidiol) oral solution, is approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC), all of which are rare diseases characterized by severe early-onset epilepsy. Epidiolex was the first plant-derived cannabinoid medicine ever approved by the U.S. Food and Drug Administration (FDA). This product has also been approved, under the tradename Epidyolex®, by the European Medicines Agency (EMA) in patients two years of age and older for the adjunctive treatment of seizures associated with LGS and Dravet syndrome in conjunction with clobazam and is under EMA review for the treatment of seizures associated with TSC. In addition to the approved indications for Epidiolex, there are considerable opportunities to pursue other indications within the epilepsy field, including other treatment-resistant epilepsies where significant unmet needs of patients exist.

Beyond Epidiolex, GW has a scientific platform and deep innovative pipeline of cannabinoid product candidates, as well as highly specialized manufacturing expertise, developed over two decades of pioneering and building leadership in cannabinoid science. This pipeline includes nabiximols, for which the company is in Phase 3 trials to seek FDA approval for treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as earlier-stage cannabinoid product candidates for autism and schizophrenia.

“Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business. We are excited to add GW’s industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities,” said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals. “We are joining two teams that share a passion for, and track record of, developing differentiated therapies that advance science and transform the lives of patients. This will help facilitate a successful integration and bring added capabilities to Jazz. Given the strength of our balance sheet and the meaningful financial drivers of the transaction, we are confident in the value we can deliver to both companies’ shareholders and patients. We look forward to welcoming the GW team to Jazz to build an even stronger company.”

“Over the last two decades, GW has built an unparalleled global leadership position in cannabinoid science, including the successful launch of Epidiolex, a breakthrough product within the field of epilepsy, and a diverse and robust neuroscience pipeline. We believe that Jazz is an ideal growth partner that is committed to supporting our commercial efforts, as well as ongoing clinical and research programs,” said Justin Gover, CEO of GW Pharmaceuticals. “We have a shared vision of developing and commercializing innovative medicines that address significant unmet needs in neuroscience and an approach of putting patients first. Together, we will have an opportunity to reach and impact more patients through a broader portfolio of neuroscience-focused therapies than ever before.”

Adoption Of Innovative Materials Or Manufacturing Bioplastic Packaging To Boost Growth Of Global Bioplastic Packaging Market 2019-2023 –

UNITED KINGDOM: The global bioplastic packaging market is expected to post a CAGR of over 18% during the period 2019-2023, according to the latest market research report by Technavio.

Factors such as increasing environmental concerns are leading to higher consumer preference for biodegradable packaging materials. To cater to the consumer demands, many end-users such as retailers and food processing companies are focusing on offering products in bioplastic packaging. Therefore, the rise in adoption of bioplastic packaging by various end-users will fuel market growth during the forecast period.

As per Technavio, the adoption of innovative materials for manufacturing bioplastic packaging will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global bioplastic packaging market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Global bioplastic packaging market: Adoption of innovative materials for manufacturing bioplastic packaging

The demand for bioplastic packaging is growing rapidly, owing to the rising need for eco-friendly and sustainable packaging from various end-user industries. There has been a rise in the adoption of various plant-based raw materials such as fruit skins, hemp, and sugarcane for manufacturing bioplastic packaging. Hemp is being adopted as a useful raw material for producing bioplastic. Furthermore, bioplastic polymers such as polyhydroxyalkanoate are being derived from microorganisms that feed on seaweed as well. Thus, the use of such eco-friendly raw materials for manufacturing bioplastic packaging is likely to drive the market during the forecast period.

“Apart from the adoption of innovative materials for manufacturing bioplastic packaging, the continuous development of new products, advances in nano-reinforcement of bioplastic packaging, government initiatives, and the rising awareness of sustainable packaging solutions are factors that will boost the growth of the global market,” says a senior analyst at Technavio.

Global bioplastic packaging market: Segmentation analysis

This market research report segments the global bioplastic packaging market by type (rigid and flexible) and geographical regions (Europe, North America, APAC, South America, MEA).

The European region led the market in 2018, followed by North America, APAC, South America, and MEA respectively. However, during the forecast period, the APAC region is expected to register the highest incremental growth due to the significant increase in the use of bioplastic packaging for pharmaceutical applications.